Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study

Respir Investig. 2023 Nov;61(6):802-814. doi: 10.1016/j.resinv.2023.08.008. Epub 2023 Sep 30.

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly since 2019, and the number of reports regarding long COVID has increased. Although the distribution of long COVID depends on patient characteristics, epidemiological data on Japanese patients are limited. Hence, this study aimed to investigate the distribution of long COVID in Japanese patients. This study is the first nationwide Japanese prospective cohort study on long COVID.

Methods: This multicenter, prospective cohort study enrolled hospitalized COVID-19 patients aged ≥18 years at 26 Japanese medical institutions. In total, 1200 patients were enrolled. Clinical information and patient-reported outcomes were collected from medical records, paper questionnaires, and smartphone applications.

Results: We collected data from 1066 cases with both medical records and patient-reported outcomes. The proportion of patients with at least one symptom decreased chronologically from 93.9% (947/1009) during hospitalization to 46.3% (433/935), 40.5% (350/865), and 33.0% (239/724) at 3, 6, and 12 months, respectively. Patients with at least one long COVID symptom showed lower quality of life and scored higher on assessments for depression, anxiety, and fear of COVID-19. Female sex, middle age (41-64 years), oxygen requirement, and critical condition during hospitalization were risk factors for long COVID.

Conclusions: This study elucidated the symptom distribution and risks of long COVID in the Japanese population. This study provides reference data for future studies of long COVID in Japan.

Keywords: General fatigue; Oxygen requirement; Patient-reported outcome; Post-COVID-19 conditions; Risk factors.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • COVID-19* / epidemiology
  • East Asian People
  • Female
  • Humans
  • Middle Aged
  • Post-Acute COVID-19 Syndrome* / epidemiology
  • Prospective Studies
  • Quality of Life
  • SARS-CoV-2